Antibody-drug conjugate development: opening windows for <i>EGFR</i>-mutant EGFR tyrosine kinase inhibitor-resistant non-small cell lung cancers? | Transl Lung Cancer Res;13(4): 936-939, 2024 Apr 29. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

VHL Regional Portal

Information and Knowledge for Health

Subject descriptor lookup Advanced Search EVID@Easy

Antibody-drug conjugate development: opening windows for EGFR-mutant EGFR tyrosine kinase inhibitor-resistant non-small cell lung cancers?

Hida, Toyoaki.

Affiliation

Hida T; Lung Cancer Center, Central Japan International Medical Center, Minokamo, Japan.

Transl Lung Cancer Res ; 13(4): 936-939, 2024 Apr 29.

Article in En | MEDLINE | ID: mdl-38736493

Key words

Antibody-drug conjugates (ADCs); EGFR-tyrosine kinase inhibitor resistance (EGFR-TKI resistance); MET gene alterations; biparatopic antibodies (biparatopic Abs); bystander effect

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Transl Lung Cancer Res Year: 2024 Document type: Article Affiliation country: Japan Country of publication: China

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Transl Lung Cancer Res Year: 2024 Document type: Article Affiliation country: Japan Country of publication: China